MX2010009575A - Derivados de pirazinonas como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso en el tratamiento de la diabetes. - Google Patents

Derivados de pirazinonas como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso en el tratamiento de la diabetes.

Info

Publication number
MX2010009575A
MX2010009575A MX2010009575A MX2010009575A MX2010009575A MX 2010009575 A MX2010009575 A MX 2010009575A MX 2010009575 A MX2010009575 A MX 2010009575A MX 2010009575 A MX2010009575 A MX 2010009575A MX 2010009575 A MX2010009575 A MX 2010009575A
Authority
MX
Mexico
Prior art keywords
diabetes
treatment
insulin secretion
obtaining
methods
Prior art date
Application number
MX2010009575A
Other languages
English (en)
Inventor
Micheline Kergoat
Gerard Botton
Samer Elbawab
Christine Charon
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2010009575A publication Critical patent/MX2010009575A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Derivados de pirazinona de fórmula (I), donde n, R1, R2, R3 y R4 tienen los valores que se definen en la reivindicación 1, como estimulantes de la secreción de insulina. La invención también se relaciona con la preparación y el uso de estos derivados de pirazinona para la profilaxis y/o el tratamiento de la diabetes y patologías asociadas.
MX2010009575A 2008-03-05 2009-01-15 Derivados de pirazinonas como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso en el tratamiento de la diabetes. MX2010009575A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08004193 2008-03-05
PCT/EP2009/000213 WO2009109259A1 (en) 2008-03-05 2009-01-15 Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes

Publications (1)

Publication Number Publication Date
MX2010009575A true MX2010009575A (es) 2010-09-24

Family

ID=40565210

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010009575A MX2010009575A (es) 2008-03-05 2009-01-15 Derivados de pirazinonas como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso en el tratamiento de la diabetes.

Country Status (18)

Country Link
US (2) US8637522B2 (es)
EP (1) EP2250156B1 (es)
JP (1) JP5530370B2 (es)
KR (1) KR101637381B1 (es)
CN (1) CN101945858B (es)
AR (1) AR070798A1 (es)
AU (1) AU2009221328B2 (es)
BR (1) BRPI0908544A2 (es)
CA (1) CA2717753C (es)
DK (1) DK2250156T3 (es)
EA (1) EA021325B1 (es)
ES (1) ES2543598T3 (es)
HU (1) HUE025132T2 (es)
IL (1) IL207719A (es)
MX (1) MX2010009575A (es)
PT (1) PT2250156E (es)
WO (1) WO2009109259A1 (es)
ZA (1) ZA201007060B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
CN102260268B (zh) * 2011-06-19 2013-04-03 漆又毛 苄硫基乙酰胺基乙酰吡嗪三唑衍生物及制备与应用
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH609989A5 (en) * 1974-06-21 1979-03-30 Hoffmann La Roche Process for the preparation of acyl derivatives
EP0008864A1 (en) * 1978-08-15 1980-03-19 FISONS plc Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them
US6159980A (en) 1996-09-16 2000-12-12 Dupont Pharmaceuticals Company Pyrazinones and triazinones and their derivatives thereof
WO2007071646A1 (en) * 2005-12-21 2007-06-28 Janssen Pharmaceutica N.V. Novel substituted pyrazinone derivatives for use in mch-1 mediated diseases
US20090011994A1 (en) * 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods

Also Published As

Publication number Publication date
US20140100235A1 (en) 2014-04-10
US20110015210A1 (en) 2011-01-20
IL207719A (en) 2015-05-31
JP5530370B2 (ja) 2014-06-25
ZA201007060B (en) 2011-06-29
BRPI0908544A2 (pt) 2015-09-29
DK2250156T3 (en) 2015-08-03
KR101637381B1 (ko) 2016-07-07
US8637522B2 (en) 2014-01-28
EP2250156B1 (en) 2015-05-06
IL207719A0 (en) 2010-12-30
WO2009109259A1 (en) 2009-09-11
US9102632B2 (en) 2015-08-11
PT2250156E (pt) 2015-09-09
CA2717753A1 (en) 2009-09-11
HUE025132T2 (en) 2016-01-28
AU2009221328B2 (en) 2014-02-27
ES2543598T3 (es) 2015-08-20
EA201001408A1 (ru) 2011-06-30
JP2011513344A (ja) 2011-04-28
AU2009221328A1 (en) 2009-09-11
AR070798A1 (es) 2010-05-05
CN101945858A (zh) 2011-01-12
EP2250156A1 (en) 2010-11-17
KR20100123900A (ko) 2010-11-25
CA2717753C (en) 2016-09-13
EA021325B1 (ru) 2015-05-29
CN101945858B (zh) 2014-05-21

Similar Documents

Publication Publication Date Title
MX2010009576A (es) Derivados de quinoxalinona como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso en el tratamiento de la diabetes.
MX2010009575A (es) Derivados de pirazinonas como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso en el tratamiento de la diabetes.
TN2012000249A1 (en) Pyrazine derivatives and their use in the treatment of neurological disorders
IN2012DN01233A (es)
UA98961C2 (uk) Похідні піразинону та їх застосування у лікуванні легеневих захворювань
MX2012004525A (es) Compuestos.
MX2012001070A (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurologicos.
MX2009009416A (es) Derivados de bencimidazol y sus metodos de uso.
IL185808A0 (en) Amide-substituted 8-n-benzimidazoles, metohd for the production thereof, and use of the same as medicaments
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
UA102858C2 (ru) Производные пиридино-пиридинонов, способ их получения и применения в терапии
TW200616985A (en) Salicylthiazoles substituted by diphenylamine or diphenylamine derivatives, process for their preparation and their use
MX2010009922A (es) Activadores de piridazinona glucocinasa.
MX342947B (es) Tratamiento de diabetes tipo 2.
MX2012007582A (es) Compuestos de 4-fenoxi-nicotinamida o 4-fenoxi-pirimidina-5-carbox amida.
MX2010009577A (es) Derivados de piridopirazinona que estimulan la secrecion de insulina, metodos para obtenerlos y su uso en el tratamiento de la diabetes.
MX2011008360A (es) Derivados de piridazinona sustituida con heteroarilo.
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
UA103191C2 (ru) Производные арилпиразинона как стимуляторы секреции инсулина, способ их получения (варианты) и их применение для лечения диабета
MX2010009837A (es) Tiazolil-dihidro-indazoles.
TN2011000531A1 (en) 5- alkynyl - pyridines
MX2010009999A (es) Derivados de amidas del acido 3-trifluorometil-pirazina-2-carboxil ico como agentes para aumentar el colesterol de lipoproteinas de alta densidad.
PL1904511T3 (pl) Homogemcytabiny
MA33958B1 (fr) Derives de pyrazine et leur utilisation dans le traitement de troubles neurologiques
MX2010009382A (es) Derivados de 4-aminociclohexano sustituidos para tratamiento de dolor.

Legal Events

Date Code Title Description
FG Grant or registration